Atlas Trials

Immunotherapy Gastroesophageal Junction

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Immunotherapy Gastroesophageal Junction

RecordFirmDate
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction (NCT06396585)Fujian Cancer Hospital2024-08-01

Track Immunotherapy Gastroesophageal Junction automatically

Every clearance here is in the API, with alerts when new ones post.